Generic Pharmaceuticals and Patents: FDA Grants Orphan Drug Status …
FDA Grants Orphan Drug Status for Personalized Lymphoma Vaccine. Jan 7, 2010 - Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID, Biovest’s personalized lymphoma vaccine. BiovaxID represents a new class of active immunotherapy and is one of the few select late-stage patient-specific cancer vaccines vying to be among the first to reach market. The details can be read here. …
Go here to see the original:
Generic Pharmaceuticals and Patents: FDA Grants Orphan Drug Status …
Stumble Upon
Del.icio.us
Buzz
